

NOTA DE PRENSA

25 de febrero de 2026



Amadix selected as one of the 8 winners of ACCIÓN, the innovative healthcare project accelerator by AstraZeneca, Wayra and Kunsen, to drive solutions that will shape the future of the healthcare system

- The early cancer detection company has been selected among nearly one hundred healthcare innovation projects that applied as candidates.
- The 8 winning startups will take part in a mentorship program over the next 6 months.

Amadix, the Spanish early cancer detection company, has been selected as one of the 8 winners of the ACCIÓN accelerator, a mentorship program promoted by AstraZeneca Spain in collaboration with Wayra, Telefónica's corporate venture capital arm, and Kunsen, an investor specialized in digital health and startup acceleration.

On February 4th, AstraZeneca's Madrid offices hosted "Pitch Day", a session that provided an opportunity to share the real needs of the healthcare environment and technological solutions with practical applications. Lourdes Planelles, Chief Scientific Officer at Amadix, presented Diagnolung, a project for the early detection of lung cancer that integrates blood biomarkers, imaging, and risk factors with artificial intelligence to assess malignancy in pulmonary nodules.

The other 7 selected companies are Synthetrial and MiMIAT Health for the healthcare system challenge; Chronity and Medsys AI for the respiratory challenge; Sycal Medical in the oncology field; and DIABYUDA and CORSONIC for the cardio-renal challenge.

Mentorship program over the next 6 months

The 8 winning startups will receive a top-tier mentorship program with individualized and personalized support; visibility and positioning at technology, healthcare and entrepreneurship events; and access to a unique network of investors and entrepreneurs to foster high-quality networking.

The program began on February 11th and will run over the next 6 months, during which the Amadix team will have the opportunity to put into practice all the knowledge acquired with the support of AstraZeneca.

You can read AstraZeneca's press release at the following link:

https://www.astrazeneca.es/medios/notas-prensa/2026/AstraZeneca_Wayra_y_Kunsen_seleccionan_proyectos_innovadores_lideres_para_impulsar_soluciones_de_salud_digital_en_Espana.html

Amadix

Amadix is a biotechnology company based in Valladolid, founded in 2010 and which specializes in early cancer detection. It conducts blood analyses that, through artificial intelligence, combine biomarkers, imaging and clinical data to develop algorithms that predict the presence of cancer cells before the first symptoms of the disease appear.

The company has received important awards and recognitions, including the European Commission's "Seal of Excellence" and the "Best Start-up" award at the South Summit in 2018.

Press Contact

Enrique Marchán| Communication Specialist

 emarchan@amadix.com

 +34 983 102 060

 +34 663 070 928

 C. Juan Hurtado de Mendoza 7, 1ª planta,
28036 Madrid

Elena Sánchez Viñes| COO

 esanchez@amadix.com

 +34 983 102 060

 +34 609 644 973

 C. Acera de Recoletos, 2, 1B, 47004 Valladolid